Oncology and Hematology - Global Oncology Academy

289-304 of 790

Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Pavani Chalasani, MD, MPH; Timothy Yap, MBBS, PhD, FRCP
- Pavani Chalasani, MD, MPH
- Timothy Yap, MBBS, PhD, FRCP
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Alexandria May, PharmD, BCPS; Nicholas Whipple, MD, MPH
- Alexandria May, PharmD, BCPS
- Nicholas Whipple, MD, MPH
Tracking Tumor Resistance in Metastatic Breast Cancer Care
Tracking Tumor Resistance in Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast Cancer
Tracking Tumor Resistance in Metastatic Breast Cancer Care
Ryan Quigley; Megan Kruse, MD
- Ryan Quigley
- Megan Kruse, MD
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstracts
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Ryan Quigley; Kathrin M. Bernt, MD
- Ryan Quigley
- Kathrin M. Bernt, MD
- Rushabh Mehta, BS
- Fatemeh Alikarami
DESTINY-Breast05: Additional Data From the Interim Analysis
DESTINY-Breast05: Additional Data From the Interim Analysis
Oncology and Hematology
DESTINY-Breast05: Additional Data From the Interim Analysis
Charles E. Geyer Jr., MD, FACP
- Charles E. Geyer Jr., MD, FACP
MinuteCE®
Beyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
A.J. Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD
1.00 credit 10 episodes
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
- Chelsea Cole, MD
1.00 credit 10 episodes
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
MinuteCE®
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
A.J. Gelderblom, MD, PhD; Chelsea Cole, MD
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Chelsea Cole, MD
1.00 program credit
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
MinuteCE®
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
MinuteCE®
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
All Sides of the Joint: Integrated TGCT Care Across Specialties
All Sides of the Joint: Integrated TGCT Care Across Specialties
MinuteCE®
All Sides of the Joint: Integrated TGCT Care Across Specialties
A.J. Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
- Chelsea Cole, MD
1.00 program credit
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
MinuteCE®
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
DESTINY-Breast11: Clinically Relevant Adverse Events
DESTINY-Breast11: Clinically Relevant Adverse Events
Oncology and Hematology
DESTINY-Breast11: Clinically Relevant Adverse Events
Charles E. Geyer Jr., MD, FACP
- Charles E. Geyer Jr., MD, FACP
Additional Safey Data From TROPION-Breast02 and Study Design of TROPION-Breast06
Additional Safey Data From TROPION-Breast02 and Study Design of TROPION-Breast06
Oncology and Hematology
Additional Safey Data From TROPION-Breast02 and Study Design of TROPION-Breast06
Komal Jhaveri, MD, FACP
- Komal Jhaveri, MD, FACP
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
MinuteCE®
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
A.J. Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
1.00 program credit
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit

19/11